Back to Discover

AVTX · Biotech · Nasdaq · As of 21 Nov 2026

Avalo Therapeutics, Inc. stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
36

Weak · 36 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

Low

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Not scored — outside AIR's $300M–$20B fundamentals band

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Pre-revenue — no valuation basis

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Weak

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Watch

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Discovery Gap: Low (0/100) · Gap confidence 45/100

Discovery gap

The market has largely caught up to the documented story.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: -3Slipped -3 on softer inputs.
Window31 Oct 2026 → 21 Nov 2026
Safety-2Weighed on the score this month.
Momentum-1Weighed on the score this month.

Evidence timeline

What changed — last 90 days

As of 13 Nov 2026
  1. The company entered into an at-the-market offering agreement with Jefferies for up to $200M in common stock sales and terminated its prior TD Cowen sales agreement.

    Major contract · 8-K filed 5 Nov →

  2. The company reported Q3 2026 results including Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa, with Phase 3 initiation planned H1 2027 and cash of $462.8M.

    Results · 8-K filed 5 Nov →

  3. The company filed its quarterly report for the period ending September 30, 2026.

    Quarterly/annual report · 10-Q filed 5 Nov →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Tue 23 Mar · expected 10-K

    Last year filed 23 Mar 2026.

  3. Thu 13 May · expected 10-Q

    Last year filed 13 May 2026.

  4. Filed
  5. Thu 5 Nov · 8-K

    8-K · Items 1.01, 1.02 — Material agreement

    Avalo entered into an at-the-market offering agreement with Jefferies for up to $200M in common stock sales and terminated its prior TD Cowen sales agreement. No immediate capital raise or business impact disclosed.

  6. Thu 5 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    Avalo reported Q3 2026 results with positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa, planning Phase 3 initiation H1 2027. Strong cash position of $462.8M funds operations into 2029. AVTX-010 IND submission planned H1 2027.

  7. Thu 5 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

  8. Thu 6 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  9. Thu 6 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  10. Tue 23 Jun · 8-K

    8-K · Item 5.02 — Director or officer change

  11. Tue 16 Jun · 8-K

    8-K · Item 8.01 — Other events

  12. Fri 12 Jun · 8-K

    8-K · Items 3.02, 3.03, 5.02 — Unregistered sale of shares

  13. Mon 8 Jun · 8-K

    8-K · Item 5.02 — Director or officer change

  14. Wed 13 May · 8-K

    8-K · Item 2.02 — Results of operations

  15. Wed 13 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  16. Thu 7 May · 8-K

    8-K · Items 1.01, 2.02 — Material agreement

  17. Tue 5 May · 8-K

    8-K · Item 8.01 — Other events

  18. Tue 28 Apr · 8-K

    8-K · Item 1.01 — Material agreement

  19. Fri 27 Mar · 8-K

    8-K · Item 5.02 — Director or officer change

  20. Mon 23 Mar · 8-K

    8-K · Item 2.02 — Results of operations

  21. Mon 23 Mar · 10-K

    Annual report (10-K), FY2025

  22. Mon 12 Jan · 8-K

    8-K · Items 2.02, 8.01 — Results of operations

  23. Tue 2 Dec · 8-K

    8-K · Item 8.01 — Other events

Earlier →

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, further risk-signal deterioration, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.